Distribuzione geografica
Continente #
NA - Nord America 7489
EU - Europa 758
AS - Asia 314
SA - Sud America 3
AF - Africa 1
Totale 8565
Nazione #
US - Stati Uniti d'America 7481
CN - Cina 276
IT - Italia 210
FI - Finlandia 138
SE - Svezia 96
DE - Germania 95
UA - Ucraina 82
FR - Francia 40
GB - Regno Unito 40
IE - Irlanda 38
VN - Vietnam 19
IN - India 10
CA - Canada 5
SI - Slovenia 5
JP - Giappone 3
KR - Corea 3
MX - Messico 3
CL - Cile 2
ES - Italia 2
PT - Portogallo 2
AT - Austria 1
BO - Bolivia 1
DK - Danimarca 1
GR - Grecia 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LU - Lussemburgo 1
LV - Lettonia 1
MA - Marocco 1
MO - Macao, regione amministrativa speciale della Cina 1
NL - Olanda 1
PL - Polonia 1
RO - Romania 1
RU - Federazione Russa 1
TH - Thailandia 1
Totale 8565
Città #
Fairfield 1341
Woodbridge 863
Houston 736
Chandler 627
Ann Arbor 571
Ashburn 525
Seattle 504
Cambridge 492
Wilmington 463
Jacksonville 308
Princeton 175
San Diego 139
Roxbury 87
Des Moines 75
Boardman 66
Beijing 64
Helsinki 60
Medford 60
Nanjing 59
Padova 57
Dublin 38
Dearborn 31
Shenyang 24
Falls Church 22
Nanchang 20
Dong Ket 19
Guangzhou 17
Norwalk 17
Hebei 16
Redwood City 16
London 14
Kharkiv 13
Changsha 11
Jiaxing 10
Hefei 9
Kunming 8
Milan 8
Vicenza 7
Camponogara 6
Hanover 6
Aprilia 5
Borås 5
Chicago 5
Crotone 5
Jinan 5
Bergamo 4
Nürnberg 4
Tianjin 4
Abano Terme 3
Berlin 3
Buffalo 3
Florence 3
Fuzhou 3
Palermo 3
Pietro 3
San Francisco 3
Taiyuan 3
Verona 3
Wuhan 3
Zhengzhou 3
Aversa 2
Chengdu 2
Frankfurt am Main 2
Las Vegas 2
Los Angeles 2
New York 2
Orsay 2
Pianiga 2
Rome 2
Rovigo 2
Taizhou 2
Torino 2
Yellow Springs 2
Auburn Hills 1
Baotou 1
Bolzano 1
Boston 1
Bucharest 1
Cadoneghe 1
Cartagena 1
Cergy 1
Chaoyang 1
Clearwater 1
Cochabamba 1
Copenhagen 1
Dallas 1
Desio 1
Dro 1
Easton 1
Figline Valdarno 1
Hangzhou 1
Indiana 1
Irving 1
Jesolo 1
La Quinta 1
Langfang 1
Leeds 1
Ljubljana 1
Luxembourg 1
Manchester 1
Totale 7710
Nome #
4,6-Diphenylpyridines as Promising Novel Anti-Influenza Agents Targeting the PA-PB1 Protein-Protein Interaction: Structure-Activity Relationships Exploration with the Aid of Molecular Modeling 163
The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: Results of a randomized, controlled clinical trial 150
Strategies and methods in monitoring and targeting protein-protein interactions. 148
Synthesis and biological evaluation of a library of hybrid derivatives as inhibitors of influenza virus PA-PB1 interaction 137
A Broad anti-influenza hybrid small molecule that potently disrupts the interaction of polymerase acidic protein-basic protein 1 (PA-PB1) subunits 134
Role of homodimerization of human cytomegalovirus DNA polymerase accessory protein UL44 in origin-dependent DNA replication in cells. 132
Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo' 132
Antiviral strategies against influenza virus: towards new therapeutic approaches. 131
Drug Repurposing for Viral Infectious Diseases: How Far Are We? 129
Simple determination of the HIV protease inhibitor atazanavir in human plasma by high-performance liquid chromatography with UV detection 128
Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase. 128
Drug Repurposing Approach Identifies Inhibitors of the Prototypic Viral Transcription Factor IE2 that Block Human Cytomegalovirus Replication 125
The isoquinoline alkaloid berberine inhibits human cytomegalovirus replication by interfering with the viral Immediate Early-2 (IE2) protein transactivating activity 119
Early inhibitors of human cytomegalovirus: State-of-art and therapeutic perspectives. 118
Potent and broad-spectrum cycloheptathiophene-3-carboxamide compounds that target the PA-PB1 interaction of influenza virus RNA polymerase and possess a high barrier to drug resistance 116
Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin 115
Development of a simple HPLC-UV method for the determination of the hepatitis C virus inhibitor simeprevir in human plasma 115
Design, synthesis, and evaluation of WC5 analogues as inhibitors of human cytomegalovirus Immediate-Early 2 protein, a promising target for anti-HCMV treatment. 112
4th European Seminars in Virology on Oncogenic and Oncolytic Viruses, in Bertinoro (Bologna), Italy 112
Development and validation of a simple and robust HPLC method with UV detection for quantification of the hepatitis C virus inhibitor daclatasvir in human plasma 112
Identification and Characterization of an Extracellular Protease Activity Produced by the Marine Vibrio sp. 60. 112
Effect of neutral and acidic phospholipids on mitochondrial ATP synthase secondary structure. 110
Construction of a fusion protein between B subunit of E. coli heat-labile enterotoxin and the C-terminus of herpes simplex virus-DNA polymerase. 110
The 6-Aminoquinolone WC5 Inhibits Different Functions of the Immediate-Early 2 (IE2) Protein of Human Cytomegalovirus That Are Essential for Viral Replication. 110
Efficient extracellular production of hybrid E. coli heat-labile enterotoxin B subunits in a marine vibrio. 109
The Sp1 transcription factor does not directly interact with the HIV-1 Tat protein 109
Kinetics of Linezolid in Continuous Renal Replacement Therapy: An in Vitro Study 109
The 6-Aminoquinolone WC5 Inhibits Human Cytomegalovirus Replication at an Early Stage by Interfering with the Transactivating Activity of Viral Immediate-Early 2 Protein 104
Optimization of Small-Molecule Inhibitors of Influenza Virus Polymerase: From Thiophene-3-Carboxamide to Polyamido Scaffolds 104
The flexible loop of the human cytomegalovirus DNA polymerase processivity factor ppUL44 is required for efficient DNA binding and replication in cells 103
Effect of differential growth conditions on the dTTP pool size in herpes simplex virus-infected Vero cells. 102
Structural investigation of cycloheptathiophene-3-carboxamide derivatives targeting influenza virus polymerase assembly. 102
HPV16 E6 and E7 upregulate the histone lysine demethylase KDM2B through the c-MYC/miR-146a-5p axys 99
Exploring the cycloheptathiophene-3-carboxamide scaffold to disrupt the interactions of the influenza polymerase subunits and obtain potent anti-influenza activity 99
Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant 98
A point mutation in a herpesvirus polymerase determines neuropathogenicity. 98
Analysis of the Association of the Human Cytomegalovirus DNA Polymerase Subunit UL44 with the Viral DNA Replication Factor UL84 97
Measurement of ribavirin and evaluation of its stability in human plasma by high-performance liquid chromatography with UV detection 97
Separation methods for acyclovir and related antiviral compounds 95
Protein-protein interactions as targets for antiviral chemotherapy 95
Specific inhibition of herpes virus replication by receptor-mediated entry of an antiviral peptide linked to Escherichia coli enterotoxin B subunit. 95
Analysis of the antigen specific T cell repertoires in HIV infection 94
Quantitative analysis of ribonucleotide triphosphates in cell extracts by high-performance liquid chromatography and micellar electrokinetic capillary chromatography: a comparative study. 92
Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant 92
A sensitive and validated HPLC-UV method for the quantitative determination of the new antifungal drug isavuconazole in human plasma 91
Identification of new Th peptides from the cytomegalovirus protein pp65 to design a peptide library for generation of CD4 T cell lines for cellular immunoreconstitution 90
Approaches for the generation of new anti-cytomegalovirus agents: identification of protein-protein interaction inhibitors and compounds against the HCMV IE2 protein. 90
pH-Dependent Conformational Changes and Topology of Herpesvirus Translocating Peptide in a Membrane-Mimetic Enviroment. 89
Interaction of Sp1 transcription factor with HIV-1 Tatprotein: looking for cellular partners. 88
A site-selective hyaluronan-interferonα2a conjugate for the treatment of ovarian cancer 88
Inhibition of herpesvirus and influenza virus replication by blocking polymerase subunit interactions 85
The catalytic subunit of herpes simplex virus type 1 DNA polymerase contains a nuclear localization signal in the UL42-binding region 84
How academic labs can approach the drug discovery process as a way to synergize with big pharma 84
Repurposing the clinically approved calcium antagonist manidipine dihydrochloride as a new early inhibitor of human cytomegalovirus targeting the Immediate-Early 2 (IE2) protein 84
Human cytomegalovirus DNA replication: antiviral targets and drugs. 83
The Human Cytomegalovirus DNA Polymerase Processivity Factor UL44 is Modified by SUMO in a DNA-dependent manner 83
A quantitative LumiFluo assay to test inhibitory compounds blocking p53 degradation induced by human papillomavirus oncoprotein E6 in living cells 83
Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients. 81
Residues of human cytomegalovirus DNA polymerase catalytic subunit, UL54, that are necessary and sufficient for interaction with the accessory protein UL44. 80
EDTA protects E. coli heat-labile enterotoxin B subunit-based fusion proteins from proteolytic degradation during their production by Vibrio spp. 79
Unboosted fosamprenavir is associated with low drug exposure in hiv-infected patients with mild-moderate liver impairment for hcv-related cirrhosis. 79
Binding parameters and thermodynamics of the interaction of the human cytomegalovirus DNA polymerase accessory protein, UL44, with DNA: implications for the processivity mechanism 75
Drug Repurposing Campaigns for Human Cytomegalovirus Identify a Natural Compound Targeting the Immediate-Early 2 (IE2) Protein: A Comment on "The Natural Flavonoid Compound Deguelin Inhibits HCMV Lytic Replication within Fibroblasts" 74
The Carboxy-Terminal Segment of the Human Cytomegalovirus DNA Polymerase Accessory Subunit UL44 Is Crucial for Viral Replication 73
Disruption of protein-protein interactions: towards new targets for chemotherapy. 73
A 6-Aminoquinolone Compound, WC5, with Potent and Selective Anti-Human Cytomegalovirus Activity 73
Multiple Phosphorylation Sites at the C-terminus Regulate Nuclear Import of HCMV DNA Polymerase Processivity Factor ppUL44. 73
Use of Vibrio spp. for expression of E. coli enterotoxin B subunit fusion proteins: purification and characterization of a chimera containing a C-terminal fragment of DNA polymerase from herpes virus type 1. 72
Cloning, expression, and functional characterization of the equine herpesvirus 1 DNA polymerase and its accessory subunit. 70
Efficient and regioselective one-step synthesis of 7-aryl-5-methyl- and 5-aryl-7-methyl-2-amino-[1,2,4]triazolo[1,5-a] pyrimidine derivatives 69
Human CD4 T-cell repertoires specific for opportunistic pathogens. 68
A novel small-molecule inhibitor of the human papillomavirus E6-p53 interaction that reactivates p53 function and blocks cancer cells growth 68
The cytomegalovirus DNA polymerase subunit UL44 forms a C-clamp shaped dimer. 66
1,2,4-Triazolo[1,5-a]pyrimidines: Efficient one-step synthesis and functionalization as influenza polymerase PA-PB1 interaction disruptors 66
Regulated Transport into the Nucleus of Herpesviridae DNA Replication Core Proteins 64
Quantitative analysis of ribonucleoside triphosphates (rNTPs) in human lymphoid cells by micellar electrokinetic capillary chromatography (MECC). 63
Selective anti-cytomegalovirus compounds discovered by screening for inhibitors of subunit interactions of the viral polymerase 63
Crystal structure of the B subunit of Escherichia coli heat-labile enterotoxin carrying peptides with anti-herpes simplex virus type 1 activity. 62
Sulfated Derivatives of Escherichia coli K5 Polysaccharide are Potent Inhibitors of Human Cytomegalovirus. 61
Corrigendum to “Exploring the cycloheptathiophene-3-carboxamide scaffold to disrupt the interactions of the influenza polymerase subunits and obtain potent anti-influenza activity” [Eur. J. Med. Chem. 138 (2017) 128–139] (S0223523417304610) (10.1016/j.ejmech.2017.06.015)) 61
Peptide inhibition of HCMV DNA polymerase processivity 60
Human Cytomegalovirus Inhibitor AL18 Also Possesses Activity against Influenza A and B Viruses. 60
The antifungal drug isavuconazole inhibits the replication of human cytomegalovirus (HCMV) and acts synergistically with anti-HCMV drugs 60
Disruption of the interactions between the subunits of herpesvirus DNA polymerases as a novel antiviral strategy. 57
Specific residues in the connector loop of the human cytomegalovirus DNA polymerase accessory protein, UL44, are crucial for interaction with the UL54 catalytic subunit. 55
Antiviral properties of new arylsulfone derivatives with activity against human betaherpesviruses 54
CD4 and CD8 epitope mapping of cytomegalovirus tegument protein pp65 for diagnostic, vaccinal and therapeutic purposes. 53
The Clinically Approved Antifungal Drug Posaconazole Inhibits Human Cytomegalovirus Replication 51
Crystal structure of the cytomegalovirus DNA polymerase subunit UL44 in complex with the C terminus from the catalytic subunit - Differences in structure and function relative to unliganded UL44 44
Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity 44
The dimeric form of hpv16 e6 is crucial to drive yap/taz upregulation through the targeting of hscrib 43
Synthesis and characterization of 1,2,4-triazolo[1,5-a]pyrimidine-2-carboxamide-based compounds targeting the PA-PB1 interface of influenza A virus polymerase 43
Intranuclear delivery of an anti-HSV-1 peptide mediated by the B-subunit of cholera-like toxin. 42
Ethyl1,8-Naphthyridone-3-carboxylates Downregulate HPV-16 E6 and E7 Oncogenes Expression 39
Divide et impera: An In Silico Screening Targeting HCMV ppUL44 Processivity Factor Homodimerization Identifies Small Molecules Inhibiting Viral Replication 38
Indomethacin-based PROTACs as pan-coronavirus antiviral agents 33
Antiviral methods and compositions 26
Author Correction: Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo’ (Nature, (2020), 584, 7821, (425-429), 10.1038/s41586-020-2488-1) 26
Intranuclear peptide delivery: a new system validated by specific inhibition of the HSV-1 DNA polymerase complex 22
Targeted disruption of e6/p53 binding exerts broad activity and synergism with paclitaxel and topotecan against hpv-transformed cancer cells 21
Totale 8597
Categoria #
all - tutte 15916
article - articoli 15194
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 114
patent - brevetti 153
selected - selezionate 0
volume - volumi 375
Totale 31752

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201868 0000 00 00 25592
2018/2019871 100855 55 849 8148303245
2019/20202414 2305940392 278206 262272 28917813771
2020/20211394 95926792 4883 62140 209129191186
2021/20221668 37152203153 118101 80208 5455174333
2022/20231244 25214134160 223224 4106 100000
Totale 8729